institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 2 days ago • loading... • Updated 2 days ago

Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001

Summary by Clinical Trials Arena

Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.The post Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 appeared first on Clinical Trials Arena.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

Clinical Trials Arena

Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001

Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.The post Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 appeared first on Clinical Trials Arena.

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated1 day agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in 2 days ago on Friday, July 25, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.